SCHEMBL1401271

SCHEMBL1401271

CCCOC(=O)CCCCN([C]=O)[Si](C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 1/20 0.46
DGKA P23743 1/20 0.46
ALDH1A1 P00352 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
EPHX2 P34913 2/20 0.38
USP2 O75604 1/20 0.37
PAM P19021 2/20 0.36
PRSS1 P07477 1/20 0.35
PRSS2 P07478 1/20 0.35
PRSS3 P35030 1/20 0.35
TOP2A P11388 1/20 0.35
MAPT P10636 2/20 0.35
MAPK1 P28482 1/20 0.35
TSHR P16473 1/20 0.34
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1401027 0.83 CYP1A2 (0.46) DNM1ALDH1A1L3MBTL1USP2TSHR
SCHEMBL33810 0.76 DGKA (0.74) DNM1DGKAALDH1A1L3MBTL1EPHX2
SCHEMBL7357559 0.76 DNM1 (0.46) DNM1DGKAALDH1A1L3MBTL1EPHX2
SCHEMBL19945901 0.75 DNM1 (0.71) DNM1DGKAALDH1A1L3MBTL1EPHX2
SCHEMBL410773 0.74 DGKA (0.78) DNM1DGKAALDH1A1L3MBTL1EPHX2
SCHEMBL494828 0.74 DGKA (0.78) DNM1DGKAALDH1A1L3MBTL1EPHX2
Hydrochloric Acid SCHEMBL11184621 0.74 DGKA (0.71) DNM1DGKAALDH1A1L3MBTL1EPHX2
SCHEMBL494910 0.74 DGKA (0.78) DNM1DGKAALDH1A1L3MBTL1EPHX2
SCHEMBL494731 0.74 DGKA (0.78) DNM1DGKAALDH1A1L3MBTL1EPHX2
SCHEMBL494154 0.74 DGKA (0.78) DNM1DGKAALDH1A1L3MBTL1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103337-A1 MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF Yamaguchi, Koushi (JP) 2023-04-06 US disclosed
US-11541040-B2 Medicine for improving state of pregnancy, and use thereof Yamaguchi, Kouchi (JP) 2023-01-03 US disclosed
EP-3977995-A1 TACROLIMUS FOR AMELIORATING PREGNANCY CONDITIONS Yamaguchi, Koushi (JP) 2022-04-06 EP disclosed
EP-3900729-A1 AGENT FOR IMPROVING INFERTILITY, RECURRENT MISCARRIAGE, AND STATE OF PREGNANCY Yamaguchi, Koushi (JP) 2021-10-27 EP disclosed
EP-3246036-B1 MEDICINE FOR IMPROVING PREGNANCY-INDUCED HYPERTENSION SYNDROME YAMAGUCHI KOUSHI (JP) 2021-10-13 EP disclosed
CN-113226331-A Medicine for improving infertility or pregnancy state 山口晃史 2021-08-06 CN disclosed
US-20210228551-A1 THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNOFETAL RELATIONSHIP YAMAGUCHI KOUSHI (JP) 2021-07-29 US disclosed
EP-3834826-A1 THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNO-FETAL RELATIONSHIP Yamaguchi, Koushi (JP) 2021-06-16 EP disclosed
CN-112533599-A Therapeutic agent for humoral immunity-related diseases in maternal-fetal relationship 山口晃史 2021-03-19 CN disclosed
WO-2020129348-A1 AGENT FOR IMPROVING INFERTILITY, RECURRENT MISCARRIAGE, AND STATE OF PREGNANCY 山口 晃史 2020-06-25 WO disclosed
EP-0483842-A1 Pharmaceutical compositions containing tricyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-05-06 EP disclosed
US-5110811-A Antibody inhibitors FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1992-05-05 US disclosed
EP-0474126-A1 Ointments containing tricyclic compound FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-03-11 EP disclosed
WO-1991019495-A1 USE OF A MACROLIDE COMPOUND SUCH AS FK 506 FOR MANUFACTURING A MEDICAMENT FOR TREATING IDIOPATHIC THROMBOCYTOPENIC PURPURA AND BASEDOW'S DISEASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-12-26 WO disclosed
WO-1991017754-A1 METHODS FOR TREATING AND PREVENTING INFLAMMATION OF MUCOSA AND BLOOD VESSELS USING FK 506 AND RELATED COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-11-28 WO disclosed
EP-0444659-A2 A pharmaceutical solution comprising derivatives of FK506 FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-09-04 EP disclosed
EP-0428169-A2 Aqueous liquid formulations FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-05-22 EP disclosed
EP-0423714-A2 Hair revitalizing agent FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-04-24 EP disclosed
EP-0406791-A2 Aqueous liquid composition for external use FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-01-09 EP disclosed
US-4929611-A ANTIBODY INHIBITORS FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103337-A1 MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF PGF, SLC10A1, SLC26A4 DNM1 2176/4885DGKA 2992/4885ALDH1A1 706/4885
US-11541040-B2 Medicine for improving state of pregnancy, and use thereof PGF, SLC10A1, SLC26A4 DNM1 1759/4885DGKA 2826/4885ALDH1A1 551/4885
US-20210228551-A1 THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNOFETAL RELATIONSHIP PGF, HAMP, HLA-DRB1 DNM1 2561/4885DGKA 4476/4885ALDH1A1 2911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.